Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate

In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.

Inclusion Criteria:

• Stage 1 and 2 hypertension without treatment for at least 2 weeks
• Women with no risk of becoming pregnant

Exclusion Criteria:

• Study participation could result in risk to health of subject
• Cardiovascular disease
• Secondary hypertension or stage 3 hypertension
• Myocardial infarction within the last 6 months
• Congestive heart failure
• Pulmonary edema
• Valvular alterations or rheumatic cardiopathy
• Clinically relevant conduction disorders significant arrhythmias
• Alcohol or illicit drug use
• Medication abuse
• Pregnant or nursing women